James Chambers

Interesting work by @TuftsCEVR Drug Coverage Policies And Clinical Guidelines Alignment: Most Coverage Decisions Include Additional Restrictions | Health Affairs healthaffairs.org/doi/full/10.13…

We are excited to share the first article in a new Health Affairs Scholar series by the Center for the Evaluation of Value and Risk in Health (CEVR) at @TuftsMedicalCtr. The series focuses on “Value of Strategies to Improve Health Care." academic.oup.com/healthaffairss…

What is the outlook for US payer coverage of specialty therapies in 2025? Expect more utilization management on pricey therapies. For more insights, register for CEVR's December 4 webinar led by @jchambers241 here: wellforce.zoom.us/webinar/regist…

Great overview of how the @TuftsCEVR SPEC database can inform discussions around emerging trends in specialty drug coverage. #amcpnexus2024 @jchambers241

Great poster at #amcpnexus 2024 from @Impacteduc on commercial health plan coverage of anti-VEGF therapies for retinal eye diseases. Plans included step therapy in 54% of coverage policies, most often through bevacizumab. @jchambers241

Join us in Las Vegas for #AMCPNexus 2024 for 2 educational sessions by @jchambers241 and @mollytoba's presentation of Fariel LaMountain's Platinum Ribbon-winning research on adalimumab product coverage. A full list of CEVR participation can be found here: cevr.tuftsmedicalcenter.org/news/spec-part…

One month from today in Boston, the special symposium on cost-effectiveness analysis. Panel 2 of 5 panels is featured below. @socmdm. Join us!

Ultra-orphan drugs bring larger health benefits than orphan/non-orphan drugs, but tend to be less cost-effective. Read new research in @ISPORJournals from current/former CEVRs Clifford, @adelealexandr, Enright, @PeterNeumann11, and @jchambers241 tinyurl.com/47t95n3k

Does #biosimilar underutilization foretell a broken biologics market? CEVR’s LaMountain, @mollytoba, @jchambers241 and @genentech's Wong and Kim used #SPEC data to study 4 biologics w/ biosimilars. Read in @Health_Affairs scholar: tinyurl.com/mryxbmcw #HAScholar

In today’s @Health_Affairs Forefront, CEVR’s @adelealexandr, @jchambers241, and Genentech’s Stacey Kowal argue Medicare drug price negotiations should consider non-clinical benefits to patients/families as part of unmet need. #IRA #Pharma tinyurl.com/2s4ftjkn

Are you passionate about health policy, evidence, and understanding the value of health care interventions? Apply to join CEVR as a Research Associate II today! tinyurl.com/ku9pkh6b #HEOR #Hiring

2. SPEC #DatabaseCoordinator: Maintain & grow the SPEC Database. Work closely with our research team to examine patient access to specialty therapies. tinyurl.com/mrrnbcvb Apply now & be part of cutting-edge healthcare research!

Tufts-CEVR is #hiring for TWO positions: 1. SPEC #ResearchAssistant II: Support our research on health plan coverage of medical tech, health economics, & cost-effectiveness analyses. Strong writing & organizational skills needed. tinyurl.com/2e6pwx3d

We’ve updated the CEA Registry with new search and reporting tools for sponsors. Log in to see the impact of these advances! cear.tuftsmedicalcenter.org #CEA #HEOR #healtheconomics

Friday is the deadline. Submit your 46th Annual Meeting abstract for consideration today: loom.ly/pHJW4-E

@mollytoba @TuftsCEVR @jchambers241 @PeterNeumann11 Thanks for the chat on this work. Great research and yes I grabbed a copy of annual rpt…reading material for plane trip home!! #ISPORAnnual #heor #hta

Come find me at poster 4012 to discuss @TuftsCEVR SPEC database research on commercial coverage of Accelerated Approval drugs. And grab a copy of our Annual Specialty Drug Coverage Trend Report 2024! #ISPORAnnual #heor #hta

Great to be #ISPORAnnual with my @TuftsCEVR colleagues!

The @TuftsCEVR Spring newsletter is out! Featuring new research in valuing health, how payers are covering cell & gene drugs, and other issues. tinyurl.com/42f3rny9 #heor #healtheconomics

Congratulations to the Tufts-CEVR team for another successful annual meeting!